Whole abdominal radiotherapy and concomitant @entity1487 as adjuvant therapy in advanced XXXX .

@entity1 @entity137 @entity294 @entity177 @entity1431 @entity3 @entity694 @entity1744 @entity1487
PURPOSE: This analysis was undertaken to assess whole abdomen radiation therapy and concurrent @entity1487 for @entity137 and patterns of failure in high-risk @entity694 @entity1 after curative surgical resection. METHODS: Eighteen @entity1 were treated adjuvantly after curative resection. Four @entity1 (22 percent) had Stage B and 14 (78 percent) had Stage C disease. Histology was poorly differentiated in 4 (22 percent) and moderately differentiated in 14 (78 percent) @entity1 . Four @entity1 received whole abdominal radiation only, 30 Gy at 1 Gy/day. Fourteen @entity1 had an additional locoregional boost of 9.6 to 16 Gy at 1.6 Gy/day. The liver received 19.8 Gy at 0.67 Gy/day. @entity1487 was given as a continuous infusion during therapy. RESULTS: With a median follow-up of three years, 6 of 18 (33 percent) @entity1 have relapsed. @entity177 occurred locally in 3 of 18 (17 percent) and distantly in 4 of 18 @entity1 (22 percent). Four of six (67 percent) failures occurred in the liver. The five-year actuarial survival and disease-free survival were 78 percent and 66 percent, respectively. Median elapsed time on radiotherapy was 73 days, with 5 of 18 @entity1 (28 percent) requiring two or more weeks of unplanned treatment breaks. Acute Grade 3 to 4 @entity137 ( @entity294 , @entity1431 ) occurred in 3 of 18 @entity1 (17 percent), with late complications ( @entity1744 ) occurring in 2 of 18 @entity1 (11 percent). CONCLUSIONS: Whole abdominal radiotherapy with concomitant @entity1487 appears to improve local control but not to prevent liver @entity3 . Significant @entity137 resulted in frequent interruption of therapy and protracted its course. Whether this adjuvant regimen impacts on survival or offers an advantage over locoregional irradiation remains to be studied.
